New research has significant clinical implications, particularly for young people with a high risk of type 1 diabetes.
Type 1 diabetes is an autoimmune disease affecting about 1.25 million children and adults in the United States.
Some people have a higher risk of developing type 1 diabetes than others. Age influences risk; this condition is one of the most common chronic ones to emerge in childhood.
Males are more likely to develop type 1 diabetes than females, and having a family history of the disease also increases the chances of developing it.
Geography also seems to play a role in type 1 diabetes risk. For instance, Sweden, Finland, Norway, the United Kingdom, and Sardinia have the highest incidence of type 1 diabetes, whereas China and South American countries have the lowest.
For people whose risk is high, a new study brings some interesting and hopeful insights. Researchers — led by Dr. Kevan C. Herold, from Yale University, in New Haven, CT — have found that a drug called teplizumab can delay the onset of type 1 diabetes in people with a high risk.
Dr. Herold and the team published their findings in The New England Journal of Medicine and presented them at the American Diabetes Association’s Scientific Sessions, in San Francisco, CA.